Niaspan buyers denied class cert
A federal judge in Pennsylvania has rejected a bid for class certification by end-purchasers of cholesterol medication Niaspan in their lawsuit against drugmakers AbbVie and Teva Pharmaceuticals.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10